Pelthos Therapeutics Inc. SEC filings PTHS
Pelthos Therapeutics Inc. has 253 filings in SEC EDGAR's recent list, going back to Sep 6, 2022. Its latest annual report, Form ARS, was filed on Aug 18, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 30, 2026 (material agreement, new debt, unregistered share sale, change to shareholder rights, officer or director change, bylaw or fiscal year change, shareholder vote results, regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 425 | Filing | Oct 30, 2026 | — |
| 425 | Filing | Oct 30, 2026 | — |
| EFFECT | Filing | Feb 9, 2026 | — |
| CORRESP | Letter to the SEC | Feb 9, 2026 | — |
| UPLOAD | Letter from the SEC | Feb 9, 2026 | — |
| D | Filing | Nov 19, 2025 | — |
| EFFECT | Filing | Sep 24, 2025 | — |
| CORRESP | Letter to the SEC | Sep 24, 2025 | — |
| CORRESP | Letter to the SEC | Sep 19, 2025 | — |
| UPLOAD | Letter from the SEC | Sep 5, 2025 | — |
| D | Filing | Jul 10, 2025 | — |
| DEFM14C | Filing | May 27, 2025 | — |
| PREM14C | Filing | May 9, 2025 | May 9, 2025 |
| EFFECT | Filing | Dec 19, 2024 | — |
| CORRESP | Letter to the SEC | Dec 11, 2024 | — |
| UPLOAD | Letter from the SEC | Dec 5, 2024 | — |
| EFFECT | Filing | Dec 2, 2024 | — |
| 8-K12G3 | Filing | Nov 19, 2024 | Nov 18, 2024 |
| EFFECT | Filing | Aug 6, 2024 | — |
| D | Filing | Aug 6, 2024 | — |
| D | Filing | Aug 6, 2024 | — |
| CORRESP | Letter to the SEC | Aug 2, 2024 | — |
| UPLOAD | Letter from the SEC | Aug 2, 2024 | — |
| POS EX | Filing | Apr 17, 2024 | — |
| NT 10-K | Filing | Apr 1, 2024 | Dec 31, 2023 |
| SEC STAFF LETTER | Filing | Feb 20, 2024 | — |
| POS EX | Filing | Feb 16, 2024 | — |
| CERT | Nyse american certification | Feb 15, 2024 | — |
| 8-A12B | Filing | Feb 15, 2024 | — |
| EFFECT | Filing | Feb 14, 2024 | — |
| CORRESP | Letter to the SEC | Feb 12, 2024 | — |
| CORRESP | Letter to the SEC | Feb 12, 2024 | — |
| CORRESP | Letter to the SEC | Jan 30, 2024 | — |
| UPLOAD | Letter from the SEC | Jan 25, 2024 | — |
| SEC STAFF LETTER | Filing | Jan 23, 2024 | — |
| UPLOAD | Letter from the SEC | Oct 24, 2023 | — |
| CORRESP | Letter to the SEC | Oct 13, 2023 | — |
| UPLOAD | Letter from the SEC | Sep 12, 2023 | — |
| CORRESP | Letter to the SEC | Sep 1, 2023 | — |
| CORRESP | Letter to the SEC | Jul 24, 2023 | — |
| UPLOAD | Letter from the SEC | Jul 10, 2023 | — |
| CORRESP | Letter to the SEC | Jun 30, 2023 | — |
| UPLOAD | Letter from the SEC | May 19, 2023 | — |
| CORRESP | Letter to the SEC | May 1, 2023 | — |
| UPLOAD | Letter from the SEC | Jan 23, 2023 | — |
| CORRESP | Letter to the SEC | Jan 11, 2023 | — |
| UPLOAD | Letter from the SEC | Oct 31, 2022 | — |
| DRS/A | Filing | Oct 17, 2022 | — |
| DRSLTR | Filing | Oct 14, 2022 | — |
| UPLOAD | Letter from the SEC | Oct 3, 2022 | — |
| DRS | Filing | Sep 6, 2022 | — |
Showing 51 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- PTHS (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Durham, NC
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1919246
- Former names
- Channel Therapeutics Corp (until May 27, 2025); Chromocell Therapeutics Corp (until Nov 15, 2024)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.